| Some people who got the Johnson & Johnson vaccine are worried that their shot won't hold up in the face on new coronavirus variants. To put themselves at ease, they are going out and getting added doses of messenger RNA vaccines—even though it's not clear yet that will help. Demand for the one-and-done J&J shot has suffered in part due to the perception that it's inferior to the two-dose mRNA vaccines that showed higher efficacy in clinical trials. But it is unclear if mixing vaccines will safely increase protection, and there are fresh signs that J&J's shot is a strong shield against variants. Still, people Terri Leslie are a case in point. The North Carolina resident had jumped at the chance to get a J&J shot in March, but as someone who takes an immune-suppressing medication for arthritis, she has been having misgivings. So this past week, she went out and got the first of two planned doses of Pfizer's mRNA shot. "I don't want to live in fear of getting sick," Leslie said.  A healthcare worker fills a syringe from a vial with a dose of Johnson & Johnson's Covid vaccine. Photographer: PHILL MAGAKOE/AFP Regulators say that there is no evidence that such a course will enhance protection. Both top U.S. infectious-disease expert Anthony Fauci and CDC director Rochelle Walensky have shied from endorsing the approach, and J&J itself says there's no reason for it. But evidence that mRNA shots amplify the protection offered by AstraZeneca's vaccine, which is similar to J&J's in terms of its underlying technology, has been enough to convince people like Leslie to take the plunge. Scientists in the U.S. are studying what happens when you combine shots in this manner: A National Institutes of Health trial launched in June in which fully vaccinated adults will receive booster doses of different Covid-19 vaccines. Similar studies are going on around the world. If mixing shots can work, one major advantage is it would help make it easier to get fully vaccinated in places where supplies are unevenly distributed. For now, however, mixing doses remains the province of a few people in a position and of a temperament to experiment. They just have to be willing to embrace risk. "There's a very good argument to be made that it's worth doing, but since we don't have any definitive data yet I can understand why it's not formally in the guidelines," said Paul Sax, clinical director of the division of infectious diseases at Brigham and Women's Hospital in Boston.—Riley Griffin | 
↠〖*HDvideo~〗 2020 Skyggen i mit øje PelÃcula Completa En LÃnea released 2020. story: Skyggen i mit øje PelÃcula Completa En LÃnea. ↞◬∺Skyg...
Post a Comment